ITGA5抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08945(ITGA5 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The ITGA5 antibody targets integrin alpha-5 (ITGA5), a subunit that pairs with integrin beta-1 (ITGB1) to form the heterodimeric receptor α5β1. This receptor primarily binds fibronectin, a key extracellular matrix (ECM) protein, and mediates cell adhesion, migration, and signaling. ITGA5 is involved in processes like embryogenesis, angiogenesis, wound healing, and tumor progression, making it a focus in cancer research, fibrosis, and inflammatory diseases.

Antibodies against ITGA5 are widely used to detect its expression in tissues or cells via techniques like Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), or flow cytometry. They help study ITGA5's role in cell-ECM interactions, metastasis, or drug resistance. Some antibodies block ligand binding, enabling functional studies to inhibit integrin-mediated pathways.

Commercially available ITGA5 antibodies vary in clonality (monoclonal/polyclonal), species reactivity (human, mouse, rat), and epitope specificity (e.g., extracellular domain). Validation data, including knockout controls or application-specific citations, are critical for selecting reliable reagents. Suppliers like R&D Systems, Abcam, and Thermo Fisher offer antibodies validated for specific applications.

When using ITGA5 antibodies, consider sample preparation (native vs. denatured conditions) and fixation methods, as these affect epitope accessibility. Functional blocking assays may require native, conformation-sensitive antibodies. Proper controls (e.g., isotype-matched IgG) ensure specificity in experimental settings.